Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

ESK-001-003

39 evidence topics · 4 sources

Objective
Location and study date
Recruitment and results status in the ClinicalTrials.gov record
FieldQuoted record
Overall status“Completed”
Results“No Results Posted”
Last update posted“2023-05-09”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse event incidence as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
RoleOutcome measureMeasure descriptionTime frame
Primary“Incidence of Adverse Events (AEs)”“Safety and tolerability”“Up to 14 days”
Primary“Incidence of Serious Adverse Events (SAEs)”“Safety and tolerability”“Up to 14 days”
Secondary“The area under plasma concentration-time curve from time zero extrapolated to last measurable concentration (AUCt) for ESK001 on Day 1 and Day 14”“Pharmacokinetics”“Up to 14 days”
Secondary“The area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) for ESK001 on Day1 and Day 14”“Pharmacokinetics”“Up to 14 days”
Secondary“The observed maximum plasma concentration (Cmax) for ESK001 on Day 1 and Day 14.”“Pharmacokinetics”“Up to 14 days”
Secondary“The time to reach the observed maximum plasma concentration (tmax) for ESK001 on Day 1 and Day 14.”“Pharmacokinetics”“Up to 14 days”
Secondary“Apparent plasma elimination half-life (t½λz) for ESK001 on Day 1 and Day 14”“Pharmacokinetics”“Up to 14 days”
Secondary“Apparent clearance CL(Clearance)/F for ESK001 on Day 1”“Pharmacokinetics”“Up to 14 days”
Secondary“The accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) for ESK001 on Day 14”“Pharmacokinetics”“Up to 14 days”
Secondary“The accumulation ratio for Cmax (RAC Cmax) for ESK001 on Day 14.”“Pharmacokinetics”“Up to 14 days”
Secondary“Cytokine induction of pSTAT expression and downstream cytokine production as a measure of tyk2 pathway inhibition by ESK001”“Pharmacodynamics”“14 days after first dose”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Absorption, half-life, dose proportionality, steady state, and accumulation with the tablet

“ESK‐001 was rapidly absorbed into the systemic circulation with a median T max of 1.5–3.1 h on Day 1 following a single dose, and 1.1–2.2 h on Day 14 following multiple q.d. or Q12 doses (Figure 3b, Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The mean t½ after the last dose on Day 14 ranged from 7.6 to 12.4 h across all q.d. or Q12 doses and no trend with dose or dose regimen was observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Similarly, no trend with dose was observed for geometric mean apparent steady‐state volume of distribution (Vss/F) and mean apparent total plasma clearance (CL/F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“After multiple q.d. doses and after the first dose administration of Q12 doses, AUC from time zero to time tau (AUC0–tau) appeared to increase in a dose‐proportional manner (slope estimates [95% CI] were 0.934 [0.62;1.25] and 0.992 [0.49, 1.49], respectively), although 95% CIs were wide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No definitive conclusion could be derived on dose proportionality for q.d. doses on Day 1 and for Q12 doses on Day 14.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Steady state was achieved by Day 3 following q.d. and Q12 multiple doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Following multiple q.d. doses, accumulation ratios (R ac) based on C max and AUC0–tau showed no to minimal accumulation of ESK‐001 (mean R ac C max ranged from 0.71 to 1.41 and mean R ac AUC from 0.80 to 1.39).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Following multiple Q12 doses, there was an ~ 2‐fold accumulation of ESK‐001 (mean R ac C max ranged from 1.74 to 2.17 and mean R ac AUC from 1.74 to 2.42).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The C trough levels at the highest ESK‐001 dose of 40 mg Q12 were maintained above the in vitro human whole blood (HWB) 90% pSTAT inhibitory concentration (IC90) threshold (Figure 3c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Plasma pharmacokinetic parameters by multiple-dose cohort on days 1 and 14
Cohort and day (N = 6 per cohort)Cmax, ng/mLCtrough, ng/mLTmax, hAUC0–tau, h*ng/mLt½, hCL/F, L/hRac CmaxRac AUCtau
10 mg q.d. fasted, day 1“88.2 (42.7)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“2.02 (1.01–2.04)”View highlighted excerpt for this quote“630.8 (41.1)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
10 mg q.d. fasted, day 14“99.5 (40.9)”View highlighted excerpt for this quote“11.8 (48.2)”View highlighted excerpt for this quote“1.60 (0.50–2.24)”View highlighted excerpt for this quote“795.8 (37.2)”View highlighted excerpt for this quote“9.22 (22.8)”View highlighted excerpt for this quote“12.6 (37.2)”View highlighted excerpt for this quote“1.13 (21.0)”View highlighted excerpt for this quote“1.26 (12.4)”View highlighted excerpt for this quote
20 mg q.d. fasted, day 1“171.4 (26.7)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“1.53 (0.51–2.07)”View highlighted excerpt for this quote“1338.0 (14.9)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
20 mg q.d. fasted, day 14“132.0 (93.3)”View highlighted excerpt for this quote“15.1 (65.6)”View highlighted excerpt for this quote“2.10 (1.02–2.16)”View highlighted excerpt for this quote“1102.0 (71.4)”View highlighted excerpt for this quote“9.18 (36.7)”View highlighted excerpt for this quote“18.2 (71.4)”View highlighted excerpt for this quote“0.71 (80.2)”View highlighted excerpt for this quote“0.80 (79.9)”View highlighted excerpt for this quote
20 mg Q12 fasted, day 1“132.2 (20.9)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“2.01 (0.51–2.05)”View highlighted excerpt for this quote“793.1 (24.1)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
20 mg Q12 fasted, day 14“287.1 (20.0)”View highlighted excerpt for this quote“108.7 (27.7)”View highlighted excerpt for this quote“2.06 (0.50–2.14)”View highlighted excerpt for this quote“1920.0 (17.3)”View highlighted excerpt for this quote“9.61 (7.6)”View highlighted excerpt for this quote“10.4 (17.3)”View highlighted excerpt for this quote“2.17 (32.7)”View highlighted excerpt for this quote“2.42 (25.6)”View highlighted excerpt for this quote
30 mg Q12 nonfasted, day 1“182.0 (46.6)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“2.09 (2.06–2.19)”View highlighted excerpt for this quote“1206.0 (38.7)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
30 mg Q12 nonfasted, day 14“282.7 (24.0)”View highlighted excerpt for this quote“54.2 (306.4)”View highlighted excerpt for this quote“2.20 (2.12–4.19)”View highlighted excerpt for this quote“1878.0 (31.4)”View highlighted excerpt for this quote“7.60 (14.5)”View highlighted excerpt for this quote“16.0 (31.4)”View highlighted excerpt for this quote“1.74 (25.8)”View highlighted excerpt for this quote“1.74 (10.0)”View highlighted excerpt for this quote
60 mg q.d. nonfasted, day 1“356.7 (48.6)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“3.12 (1.13–4.07)”View highlighted excerpt for this quote“2934.0 (30.7)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
60 mg q.d. nonfasted, day 14“503.8 (40.3)”View highlighted excerpt for this quote“45.5 (61.8)”View highlighted excerpt for this quote“2.09 (2.03–2.12)”View highlighted excerpt for this quote“4074.0 (33.7)”View highlighted excerpt for this quote“9.56 (20.2)”View highlighted excerpt for this quote“14.7 (33.7)”View highlighted excerpt for this quote“1.41 (34.4)”View highlighted excerpt for this quote“1.39 (30.5)”View highlighted excerpt for this quote
40 mg Q12 fasted, day 1“249.6 (25.9)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“2.06 (1.01–4.01)”View highlighted excerpt for this quote“1574.0 (25.4)”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote“‐”View highlighted excerpt for this quote
40 mg Q12 fasted, day 14“437.4 (49.0)”View highlighted excerpt for this quote“226.3 (31.3)”View highlighted excerpt for this quote“1.08 (1.04–2.13)”View highlighted excerpt for this quote“3246.0 (50.2)”View highlighted excerpt for this quote“12.41 (29.8)”View highlighted excerpt for this quote“12.3 (50.2)”View highlighted excerpt for this quote“1.75 (61.9)”View highlighted excerpt for this quote“2.06 (51.2)”View highlighted excerpt for this quote
Inhibition of IFNα-induced pSTAT1 in T cells by dose

“In the MD study, IFNα‐induced pSTAT1 expression was analyzed in T cells from whole blood as a measure of TYK2 inhibition and confirmed robust pharmacologic activity of ESK‐001 with a clear dose‐dependent effect (Figure 4a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Maximal TYK2 pathway inhibition was achieved within 2–4 h for all doses >10 mg q.d., with dose‐dependent differences observable at later timepoints following the last dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At the highest daily dose of 80 mg (administered as 40 mg Q12), maximal levels of TYK2 inhibition were achieved within 2–4 h and maintained throughout the Q12 dose interval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At the lowest total daily dose of 10 mg q.d., a partial TYK2 inhibition profile was achieved, with TYK2 inhibition peaking at <50% inhibition within 2–4 h and quickly returning to baseline TYK2 activity with minimal inhibition measured at 12 and 24 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All dose levels returned toward normal TYK2 activity 24–48 h after the last dose on Day 14.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events by multiple-dose cohort
Event10 mg q.d. fasted (N = 6)20 mg q.d. fasted (N = 6)20 mg Q12 fasted (N = 6)30 mg Q12 nonfasted (N = 6)60 mg q.d. nonfasted (N = 6)40 mg Q12 fasted (N = 6)Total active (N = 36)Pooled placebo (N = 13)
Participant with at least 1 TEAE“3 (50.0) [7]”View highlighted excerpt for this quote“5 (83.3) [11]”View highlighted excerpt for this quote“5 (83.3) [14]”View highlighted excerpt for this quote“5 (83.3) [10]”View highlighted excerpt for this quote“4 (66.7) [16]”View highlighted excerpt for this quote“5 (83.3) [14]”View highlighted excerpt for this quote“27 (75.0) [72]”View highlighted excerpt for this quote“11 (84.6) [19]”View highlighted excerpt for this quote
Mild“3 (50.0) [6]”View highlighted excerpt for this quote“5 (83.3) [10]”View highlighted excerpt for this quote“5 (83.3) [14]”View highlighted excerpt for this quote“5 (83.3) [9]”View highlighted excerpt for this quote“4 (66.7) [11]”View highlighted excerpt for this quote“5 (83.3) [14]”View highlighted excerpt for this quote“27 (75.0) [64]”View highlighted excerpt for this quote“11 (84.6) [18]”View highlighted excerpt for this quote
Moderate“1 (16.7) [1]”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“3 (50.0) [5]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“6 (16.7) [8]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
Severe“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
TEAEs considered related to the study drug“1 (16.7) [2]”View highlighted excerpt for this quote“2 (33.3) [4]”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“3 (50.0) [3]”View highlighted excerpt for this quote“4 (66.7) [11]”View highlighted excerpt for this quote“4 (66.7) [8]”View highlighted excerpt for this quote“15 (41.7) [29]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
TEAEs leading to study drug discontinuation“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (2.8) [1]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
Any serious TEAE“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Erythema“2 (33.3) [2]”View highlighted excerpt for this quote“5 (83.3) [6]”View highlighted excerpt for this quote“5 (83.3) [5]”View highlighted excerpt for this quote“4 (66.7) [5]”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“20 (55.6) [22]”View highlighted excerpt for this quote“9 (69.2) [11]”View highlighted excerpt for this quote
Headache“0”View highlighted excerpt for this quote“3 (50.0) [5]”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“4 (66.7) [9]”View highlighted excerpt for this quote“4 (66.7) [8]”View highlighted excerpt for this quote“14 (38.9) [25]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
Gastrointestinal disorders“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“2 (33.3) [2]”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“5 (13.9) [5]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
Psychiatric disorders“1 (16.7) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“2 (5.6) [2]”View highlighted excerpt for this quote“1 (7.7) [1]”View highlighted excerpt for this quote
Dysmenorrhoea“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (16.7) [1]”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (2.8) [1]”View highlighted excerpt for this quote“2 (15.4) [2]”View highlighted excerpt for this quote
Incidence, severity, relatedness, discontinuations, and laboratory findings in the multiple-dose study

“Thirty‐eight (77.6%) participants experienced 91 TEAEs; 27 (75.0%) participants receiving ESK‐001 experienced 72 TEAEs and 11 (84.6%) participants receiving placebo experienced 19 TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most TEAEs (90.1%) were mild in severity; all other TEAEs were moderate in severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There was no dose‐dependent increase in the number of TEAEs or meaningful change in the severity levels observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The frequency of headaches appeared to increase with increasing dose of ESK‐001; however, most headaches (80.8%) were observed to be mild in severity across all dose levels and resolved without sequalae.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Two participants discontinued the study drug and study due to TEAEs; one participant receiving ESK‐001 (Cohort 30 mg Q12 nonfasted) due to rash morbilliform (considered study drug‐related), and one receiving placebo (Cohort 60 mg q.d. nonfasted) due to COVID‐19 (considered not study drug‐related); both TEAEs were mild in severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most common TEAEs (reported in ≥30% of the participants in any group) by preferred term were erythema and headache.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Events of erythema were secondary to skin taping for a sample collection procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fifteen (41.7%) participants receiving ESK‐001 experienced 29 TEAEs considered related to the study drug and 1 (7.7%) participant receiving a placebo experienced a TEAE considered related to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Minor fluctuations occurred in coagulation, clinical chemistry, and urinalysis parameters, but without treatment‐related trends.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Two participants reported an abnormal clinically meaningful laboratory value; one for Strep A2 rapid screen on Day 8, and one for SARS‐CoV‐2 RNA on Day 9.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Study limitations
Summary
  • The authors advise caution in interpreting the dose proportionality analysis because of the small number of participants, the limited q.d. and Q12 dose range, and the wide 95% CIs; no definitive conclusion could be derived for q.d. doses on Day 1 and Q12 doses on Day 14.
  • Participants were 49 healthy adults (36 envudeucitinib, 13 placebo) treated for 14 days at one site.
  • The last two cohorts (30 mg Q12 and 60 mg q.d.) were dosed nonfasted, while the other cohorts were dosed fasted.
  • The Sponsor was unblinded, and five placebo participants with unexpected ESK-001 plasma concentrations were excluded at the Sponsor's request.
  • Some pharmacodynamic samples were collected on Day 13 instead of Day 14, and urine was analyzed for only 3 of the 6 cohorts, with one outlier participant raising the 20 mg q.d. means.
  • Erythema, the most common TEAE with headache, was secondary to skin taping for a sample collection procedure.
  • The article describes a parallel-group study conducted from April 15, 2022 to September 20, 2022; the ClinicalTrials.gov record lists sequential assignment, a start on 2022-05-12, and completion on 2022-12-31, and reads “No Results Posted”.